The development of erythema elevatum diutinum in a patient with juvenile idiopathic arthritis under treatment with abatacept

Golmia, Andrea Pimentel Fonseca; Grinblat, Beni; Finger, Eduardo; Klieman, Claudia; Assir, Fernanda Ferraz; Scheinberg, Morton

doi:10.1007/s10067-007-0743-6

Cited by 18 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EED is a rare form of chronic cutaneous vasculitis that is usually associated with underlying disease processes such as hematological malignancies, connective tissue disorders, chronic infections, inflammatory bowel disease, HIV and streptococcal infections (3,4). The present case is unusual in the fact that the patient had no detectable underlying illness.…”

Section: Discussionmentioning

confidence: 82%

Successful Surgical Treatment of Advanced Erythema Elevatum Diutinum

Rinard¹,

Mahabir²,

Greene

et al. 2010

Canadian Journal of Plastic Surgery

View full text Add to dashboard Cite

Erythema elevatum diutinum is a rare, chronic cutaneous vasculitis that presents with plaques or nodules on the extensor surfaces of extremities. Although the exact pathogenesis is unknown, patients usually have an underlying systemic medical problem such as malignancy, autoimmune disease or HIV. Management of the cutaneous manifestations is aimed at controlling the underlying disease process, in addition to medical therapy directed at suppressing the lesions. The difficult case of a 60-year-old man, who was not a candidate for medical therapy but has undergone successful surgical therapy of this rare disease for 10 years, is presented.

show abstract

Section: Discussionmentioning

confidence: 82%

Successful Surgical Treatment of Advanced Erythema Elevatum Diutinum

Rinard¹,

Mahabir²,

Greene

et al. 2010

Canadian Journal of Plastic Surgery

View full text Add to dashboard Cite

show abstract

“…One patient developed erythema elevatum diutinum with improvement only with topical corticosteroids and the other one developed cutaneous medium vessel vasculitis with improvement after drug withdrawal and prednisone use. [ 83 , 84 ]…”

Section: Resultsmentioning

confidence: 99%

Vasculitis induced by biological agents used in rheumatology practice: A systematic review

Duran¹,

Paz²,

Santiago³

2021

Arch Rheumatol

View full text Add to dashboard Cite

Objectives: Biological medications have been used with an increasing frequency to treat rheumatological diseases. Autoimmune events can be induced by these drugs, such as psoriasiform lesions, alopecia, lupus and, vasculitis, which more often affects the skin (small-sized vessels) and eventually other organs. In this review, we describe the clinical profile of patients with vasculitis induced by the main biological agents used in rheumatology. Patients and methods: We performed a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations. The PubMed database was used for searching eligible articles. We included case reports, case series, and letter to the editor of patients on anti-tumor necrosis factor-alpha (anti-TNF-a) molecules, as well as tocilizumab, ustekinumab, secukinumab, rituximab, and abatacept, who had vasculitis induced by these agents. Results: Eighty-one articles were included for final analysis (n=89). Twenty-seven patients were using infliximab, 20 adalimumab, 18 etanercept, seven secukinumab, four certolizumab, four rituximab, three golimumab, three ustekinumab, two abatacept, and one tocilizumab. Unspecific leukocytoclastic vasculitis (LCV) was the most common type of vasculitis (n=37), followed by anti-neutrophil cytoplasmic antibody (ANCA)- associated vasculitis (n=16). The medication was replaced with another biological molecule in 23 cases, with only four relapses. In six cases, the biological was maintained, but vasculitis worsened/persisted in one case, being necessary drug removal. Conclusion: Infections, infusion reaction, cancer, and autoimmune events are well-known side effects of biological therapy. This review demonstrates that vasculitis is another adverse effect of this type of therapy, particularly the anti-TNF-a molecules, and LCV the most reported type of vasculitis.

show abstract

“…9 The most effi cient treatment is with dapsone. 14,15 Dapsone's exact mechanism of action is not completely known, but that drug is known to stabilize the lysosomes of neutrophils or interfere with the deposition of complement factor 3. Other hypotheses about dapsone's mechanism of action are: suppression of the excessive chemotactic activity of neutrophils; inhibition of cytotoxicity of neutrophils; decrease in the concentration of infl ammation-induced oxygen intermediates; and inhibition of prostaglandins D2, which are vasoactive and increase the chemotactic potential of leukotrienes B4.…”

Section: Discussionmentioning

confidence: 99%

Eritema elevatum diutinum como diagnóstico diferencial das doenças reumatológicas: relato de caso

Rosa¹,

Machado²,

Fraga³

et al. 2012

Rev. Bras. Reumatol.

View full text Add to dashboard Cite

Erythema elevatum diutinum is a chronic and rare cutaneous leukocytoclastic vasculitis, characterized by red, purple and yellow papules, plaques and nodules, distributed symmetrically on the extensor surfaces of the limbs. It is associated with several autoimmune, neoplastic and infectious processes, mainly hematological malignancies in about 30% of the cases. Joint pain and arthritis are frequent symptoms, affecting approximately 40% of the patients, indicating the need for its inclusion in the differential diagnosis of rheumatic diseases, chiefl y the other presentations of leukocytoclastic vasculitis, which are characterized by the combination of rheumatic manifestations and peculiar cutaneous lesions. We report the case of an 18-year-old female patient who developed erythema elevatum diutinum and whose diagnosis was based on the morphologic characteristics, the distribution pattern of the cutaneous lesions and the histopathological fi ndings of leukocytoclastic vasculitis. The major systemic symptom was severe arthritis.

show abstract

The development of erythema elevatum diutinum in a patient with juvenile idiopathic arthritis under treatment with abatacept

Cited by 18 publications

References 5 publications

Successful Surgical Treatment of Advanced Erythema Elevatum Diutinum

Successful Surgical Treatment of Advanced Erythema Elevatum Diutinum

Vasculitis induced by biological agents used in rheumatology practice: A systematic review

Eritema elevatum diutinum como diagnóstico diferencial das doenças reumatológicas: relato de caso

Contact Info

Product

Resources

About